TABLE 2.
Control Subjects (n=12) |
Mutation-Positive Subjects Without Hypertrophy (n=12) |
|||
---|---|---|---|---|
Baseline | Follow-Up | Baseline | Follow-Up | |
Lateral Sa, cm/s | 15.6±2 | 15±1.2 | 8.7±1.7* | 8.2±2.1* |
Lateral Ea, cm/s | 16±2.5 | 16.5±2.8 | 9.5±2* | 8.1±2.3*† |
Lateral Aa, cm/s | 9.4±1.1 | 9.1±1.5 | 9.8±2.2 | 8.3±1.4*† |
Lateral Ea/Aa | 1.8±0.3 | 1.8±0.4 | 0.92±0.3* | 0.95±0.3* |
Lateral E/Ea | 5.4±1.45 | 5.3±1.8 | 7.99±1.4* | 10±1.7*† |
Septal Sa, cm/s | 14.5±1.4 | 13±1.2 | 7.96±1.6* | 7.4±1.9* |
Septal Ea, cm/s | 15±2 | 14.7±2.5 | 8.5±2.27* | 7.8±2.5*† |
Septal Aa, cm/s | 9.2±1.6 | 9.2±1.8 | 9.5±2.8 | 8.3±2.1*† |
Septal Ea/Aa | 1.85±0.34 | 1.8±0.26 | 0.93±0.4* | 0.94±0.2* |
Septal E/Ea | 5.8±0.92 | 5.6±0.92 | 8.65±1.5* | 10.26±2*† |
P<0.01 vs control subjects both at baseline and follow-up.
P≤0.01 vs mutation-positive subjects at baseline.